NICE rejects again Javlor (Pierre Fabre) as a treatment for Bladder Cancer

NICE (National Institute of Heatlth and Clinical Excellence) has rejected again the application from Pierre Fabre for Javlor (vinflunine) as a treatment for Bladder Cancer after platinum treatment has failed. NICE considered that there was insufficient evidence of clinical effectiveness compared to best supportive care. The 302 trial evidence could not be generalised to the entire UK population. There was no data on patients with a better prognosis than those included in the trial and NICE doubted the claim of overall survival benefit. The drug is widely available in other European countries.